Fulcrum Therapeutics, Inc. (FULC) vs SAB Biotherapeutics, Inc. (SABS)
A side-by-side comparison of Fulcrum Therapeutics, Inc. and SAB Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FULC
Fulcrum Therapeutics, Inc.
$3.70HealthcareDelayed quote: Oct 6, 2026, 2:40 PM EDT
SABS
SAB Biotherapeutics, Inc.
$2.97HealthcareDelayed quote: Oct 6, 2026, 2:40 PM EDT
Total return — FULC vs SABS
growth of $100 · dividends reinvested · last 6yFULC -70.9% (-18.6%/yr)SABS -96.9% (-44.1%/yr)FULC compounded faster over this window
Log scale — wide-divergence pair
FULC SABS
FULC vs SABS: by the numbers
- •FULC is the larger company ($282M vs $270M market cap).
Metrics side by side
Valuation
| Metric | FULC | SABS |
|---|---|---|
| P/B ratio | 0.91 | 1.26 |
Profitability
| Metric | FULC | SABS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -27.36% | -5.95% |
| ROIC | -27.62% | -31.62% |
Growth (annualized)
| Metric | FULC | SABS |
|---|---|---|
| EPS CAGR (5Y) | N/A | -50.57% |
| Total return CAGR (5Y) | -31.70% | -50.16% |
Frequently asked
- How have FULC and SABS total returns compared?
- Over the past 5 years, FULC delivered -31.70% and SABS delivered -50.16% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.